YAP1 and prostate cancer: Previous studies have shown that the Hippo pathway typically regulated activity by limiting the entry of YAP and TAZ (Transcriptional coactivator with PDZ-binding motif) into the nucleus, and the deregulation of the hippo pathway has been reported at a high frequency in a broad range of different human carcinomas, including lung, colorectal, ovarian, liver and prostate cancers [15].